Companies › Shin Poong Pharmaceutical
2 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 2; Cardiovascular, Gastroenterology, Neurology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SP-8203 (Otaplimastat) Matrix metalloproteinase inhibitor | – | Phase 3 | Ischemic Stroke | Mar 2027 |
| Candesartan (SPC1001) Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 2 | Hypertension, Essential; Cardiomyopathy, Dilated; Liver Fibroses | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06826872 | Candesartan (SPC1001) | Phase 2 | Hypertension, Essential | Cardiovascular | Oct 2025 |
| NCT05321875 | Candesartan (SPC1001) | Phase 3 | Cardiomyopathy, Dilated | Cardiovascular | Jun 2026 |
| NCT06660719 | SP-8203 (Otaplimastat) | Phase 3 | Ischemic Stroke | Neurology | Mar 2027 |
| NCT03770936 | Candesartan (SPC1001) | Phase 3 | Liver Fibroses | Gastroenterology | Nov 2027 |
THPharm HB BioTech Chong Kun Dang Pharmaceutical Yuhan Shenzhen Salubris Pharmaceuticals Travere Therapeutics Chia Tai Tianqing Pharmaceutical Group
THPharm Shenzhen Salubris Pharmaceuticals Zydus Therapeutics Livzon Pharmaceutical Group CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.